Abstract
The Acyclic Nucleoside Phosphonates (ANPs): Antonin Holy's Legacy (2012 - 2018)
Highlights
Antonín Holý died on 16 July 2012
That day the US Food and Drug Administration (FDA) approved Truvada®, the combination of TDF with emtricitabine, for the prophylaxis of HIV infections [on 22 August 2016 Truvada® was approved in the EU for the prophylaxis of HIV infections]
That Truvada® has been replaced by Descovy® [combination of tenofovir alafenamide (TAF) with emtricitabine] for the treatment of HIV infections, Descovy® may eventually be considered to substitute for Truvada® in the prevention of HIV infections, after it has been proven efficacious for PrEP
Summary
Antonín Holý died on 16 July 2012 (obituary1a,1b). Precisely that day the US Food and Drug Administration (FDA) approved Truvada®, the combination of TDF (tenofovir disoproxil fumarate) with emtricitabine, for the prophylaxis of HIV infections [on 22 August 2016 Truvada® was approved in the EU for the prophylaxis of HIV infections]. Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium *Correspondence: Dr Erik De Clercq, Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium, Email: erik.declercq@kuleuven.be
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
